Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (1631)	8/31/1999 1:38:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

Hi Celeryroot: Thanks for posting this good news. Since the earlier results were more favorable in the Type 1 group, statistical significance in Type 2 is especially welcome. While the press release didn't deal with HDL/LDL ratio, that is another favorable aspect of prior results. All in all, a good step forward today. As I noted in previous postings, the large carry over loss amounts to almost $3 a share value for a major company in the field. This now seems to be a strong underpinning for the stock price. Even the strong move today doesn't really reflect this. Regards, Arnie